[Blog] Who's funding stem cell research?
By Jim Fossett,
Bioethics.net
| 08. 14. 2007
We've been arguing for a long time here that states have been spending more on human embryonic stem cell(hESC) research than the feds, and now we have some numbers to back it up. In a piece just posted on the Rockefeller Institute of Government website, we try to tote up who's spending how much on stem cell research in general and hESC in particular. While we can't be nearly as precise as we'd like, several things are clear..
+ The feds aren't spending much at all. Total stem cell allocations via NIH has been roughly flat at $640 million annually for the last couple of years. Only about six percent of that, or roughly $40 million annually, goes for hESC research.
+ States are spending more than the feds on hESC. California by itself has already obligated more than $200 million to hESC research, making it the largest hESC funder in the world. The California Institute of Regenerative Medicine (CIRM), the state agency which manages the stem cell program, is spending more than five times what NIH is spending...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
